Do's and Don'ts for the Patient on Levodopa Therapy

1976 ◽  
Vol 76 (6) ◽  
pp. 917
Author(s):  
Rebecca J. Langan ◽  
George C. Cotzias
Keyword(s):  
Levodopa Therapy

scholarly journals Impact of levodopa treatment in the voice pattern of Parkinson’s disease patients: a systematic review and meta-analysis

CoDAS ◽  
2018 ◽  
Vol 30 (5) ◽  
Author(s):  
Patrícia Pinho ◽  
Larissa Monteiro ◽  
Maria Francisca de Paula Soares ◽  
Lorena Tourinho ◽  
Ailton Melo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Acoustic Analysis ◽  
Meta Analysis ◽  
Speech Disorders ◽  
Levodopa Therapy ◽  
Eligibility Criteria ◽  
Perceptual Analysis ◽  
Vocal Intensity

Abstract Purpose Investigate the association between levodopa therapy and vocal characteristics in Parkinson’s disease patients. Search strategy Studies published at MEDLINE, LILACS, and SciELO, from 1960 to December 2016. A systematic review and meta-analysis was performed using the following keywords: Parkinson’s disease; levodopa; L-dopa; voice; speech disorders; dysphonia; dysarthria. After analyzing titles and abstracts, two independent reviewers selected all clinical trials that met the eligibility criteria and selected the articles and the data recorded in a previously standardized table. Selection criteria Trials published in English between 1960 and December 2016 individuals with clinical diagnosis of Parkinson’s disease; use of levodopa therapy in stable doses; acoustic analysis combined or not with auditory-perceptual analysis to evaluate the vocal parameters under investigation. Data analysis The following vocal parameters were analyzed: fundamental frequency (F 0), jitter, and vocal intensity. Standardized mean differences (SMD) were calculated using the Comprehensive Meta-analysis V2 software. Results Nine articles met the eligibility criteria and were selected, with a total of 119 individuals. From these, six articles with 83 individuals were included in the meta-analysis. During the levodopa therapy “on” state, modifications in F 0 (SMD=0.39; 95% CI - 0.21-0.57) and jitter (SMD=0.23; 95% CI - 0.02-0.45) were observed. Vocal intensity was not affected (SMD=0.09; 95% CI - 0.22-0.39) by levodopa ingestion. Data of the included studies were controversial in the auditory-perceptual analysis of voice. Conclusion Levodopa therapy modifies F0 and jitter. No changes in vocal intensity were observed in either the “on” or “off” states of levodopa therapy.

Striatonigral degeneration response to levodopa therapy

1972 ◽  
Vol 16 (3) ◽  
pp. 331-341 ◽  
Author(s):  
A.H. Rajput ◽  
K.H. Kazi ◽  
B. Rozdilsky
Keyword(s):  
Levodopa Therapy ◽  
Striatonigral Degeneration

scholarly journals Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s

2016 ◽  
Vol 74 (8) ◽  
pp. 687-689 ◽  
Author(s):  
Bruno Lopes dos Santos-Lobato ◽  
Vitor Tumas
Keyword(s):  
Scientific Community ◽  
Levodopa Therapy ◽  
Scientific Contribution

ABSTRACT Most known by his literary ability, the words of the neurologist Oliver Sacks (1933-2015) also had an impact on scientific community about the role of levodopa on parkinsonisms. Different from the most authors and based on his experience described on the book “Awakenings”, he had a pessimistic opinion about levodopa, which was related on many articles written by himself and colleagues in early 1970s. We reviewed the scientific contribution of Oliver Sacks associated to levodopa therapy on parkinsonisms, and how he advised caution with its complications before the majority of physicians.

Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease

1995 ◽  
Vol 52 (6) ◽  
pp. 565-570 ◽  
Author(s):  
M. P. McDermott ◽  
J. Jankovic ◽  
J. Carter ◽  
S. Fahn ◽  
S. Gauthier ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Levodopa Therapy

Shy-Drager Syndrome. Neuropathological Correlation and Response to Levodopa Therapy

1976 ◽  
Vol 3 (3) ◽  
pp. 167-173 ◽  
Author(s):  
Jacques De Lean ◽  
John H.N. Deck
Keyword(s):  
Lewy Bodies ◽  
Sympathetic Ganglia ◽  
Levodopa Therapy ◽  
Striatonigral Degeneration ◽  
Preganglionic Neurons ◽  
Progressive Loss ◽  
System Degeneration ◽  
Nigral Degeneration ◽  
Depressor Action ◽  
Lateral Sclerosis

SUMMARY:The post-mortem examination of the nervous system of a patient with Shy-Drager syndrome successfully treated with levodopa (Sharpe et al, 1972) revealed features of striato-nigral degeneration and amyotrophic lateral sclerosis, a cerebellar system degeneration and a loss of approximately 75% of sympathetic preganglionic neurons. Lewy bodies were not present and no detectable changes were observed in the sympathetic prevertebral ganglia.While the limited and transient beneficial effect of levodopa on the bradykinesia in our case is possibly due to the progressive loss of striatal dopaminergic receptors seen in striatonigral degeneration, we propose that in Shy-Drager syndrome, levodopa therapy benefits orthostatic hypotension because of a suppression of the central depressor action of this drug. This suppression is attributable to functional disconnection of sympathetic ganglia secondary to the loss of preganglionic neurons or to degeneration of central autonomic catechoiaminergic systems.

Sign in / Sign up

Export Citation Format

Share Document